戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  cell recruitment that may contribute to its atherogenicity.
2 ortant in determining the relative degree of atherogenicity.
3  nitration, additionally contributing to its atherogenicity.
4 profiles that often correlate with increased atherogenicity.
5 f its biochemistry, genetics, metabolism and atherogenicity.
6 l, and 3) explaining the mechanisms of lipid atherogenicity.
7 e may be a feature that contributes to their atherogenicity.
8 ion of LDL, particularly with respect to its atherogenicity.
9 me B cytotoxins in promoting CD4(+) NKT cell atherogenicity.
10 RS analysis allowed direct prediction of the Atherogenicity and Thrombogenicity indexes, which are us
11 utritional standpoint, displaying the lowest atherogenicity and thrombogenicity indices (0.02 and 0.1
12                               The indices of atherogenicity and thrombogenicity were also within the
13  Oxidative modification of LDL increases its atherogenicity, and 15-lipoxygenase (15-LO) has been imp
14 holesterol lowering, anti-inflammatory, anti-atherogenicity, and anti-cancer potential.
15 ay contribute to decreased oxidative damage, atherogenicity, and cardiovascular disease.
16                Second, several mechanisms of atherogenicity are known to varying extent, but the rela
17 epatic ACAT2 could account for the increased atherogenicity associated with cholesteryl ester-enriche
18 tios, and the indices of thrombogenicity and atherogenicity depended on specific omega-3 PUFAs-rich o
19                       The mechanism of Lp(a) atherogenicity has not been elucidated, but likely invol
20 , these results indicate that CAPN6 promotes atherogenicity in inflamed macrophages by disturbing CWC
21 holesterolemic acid ratios (HH) (0.87-2.43), atherogenicity index (IA) (0.26-0.60), and thrombogenici
22                                              Atherogenicity index and desaturase activity indices wer
23                Although the mechanism of its atherogenicity is unknown, Lp(a) has been implicated in
24                                         This atherogenicity may be a reflection of the association of
25 wed us to address the question of the direct atherogenicity of chylomicrons and large VLDL.
26 ans-11 18:1) on the blood lipid profile, the atherogenicity of LDL, and markers of inflammation and i
27 sease (CAD) may enhance understanding of the atherogenicity of lipid fractions.
28 size reveals important information about the atherogenicity of lipoprotein profile.
29 s such as apolipoprotein B-100 increases the atherogenicity of low-density lipoproteins (LDL).
30   However, the underlying mechanisms for the atherogenicity of Lp(a) are not completely understood.
31                  These data suggest that the atherogenicity of Lp(a) lipoprotein may be mediated in p
32 s and chronically elevated Lp(a) levels, the atherogenicity of Lp(a) may stem from its capacity as a
33 emotaxis, providing novel mechanisms for the atherogenicity of Lp(a).
34 sights into plaque rupture and the potential atherogenicity of Lp(a).
35 O-glycans that is potentially related to the atherogenicity of Lp(a).
36 pertriglyceridemia and may contribute to the atherogenicity of nephrotic dyslipidemia.
37 s, LPL in the artery wall might increase the atherogenicity of oxidized LDL, since it enables its bin
38  composition and structure and to reduce the atherogenicity of OxLDL by decreasing its lysoPC content
39                                 The relative atherogenicity of TGRL positively correlated with partic
40 se cholesterol transport) determine the anti-atherogenicity of the HDL fraction.
41  allow us to examine experimentally the anti-atherogenicity of the HDL subclasses.
42 e of RLP by the liver as well as the general atherogenicity of these particles.
43 plasma residence time, thereby elevating the atherogenicity of these particles.
44 obesity, and type 2 diabetes, and the marked atherogenicity of this condition.
45 of LDL forms small, dense LDL with increased atherogenicity that provides a new route to atherogenic
46                                    ApoCIII's atherogenicity was traditionally attributed to hypertrig

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。